USSTOCK.TODAY
Regular Market
Log in Sign up

Travere Therapeutics beats consensus with $224.56 million in revenue

Earnings Whispers · ·by G4L

TVTX
TVTX Travere Therapeutics Inc
$51.99 +0.70%
View chart & analysis →
  1. 1Travere Therapeutics recorded $224.56 million in revenue this quarter.
  2. 2Travere Therapeutics reported a GAAP net loss per share of $0.55 this quarter, falling short of the consensus estimate of $0.25 net loss per share.
  3. 3Management reset the FILSPARI target to $3 billion by 2033.

So what's the key point?

Travere Therapeutics generated $224.56 million in revenue this quarter. However, the loss per share was larger than what experts expected, so it remains to be seen if the stock will rise further.

Source Earnings Whispers · View original ↗

Related 3-line summaries

Travere Therapeutics Reports $224.6 Million in Third Quarter Revenue The Motley Fool +1 · Nov 3Guardant Health Ordered to Pay $245.2M for DNA Sequencing Patent Infringement Investor's Business Daily +1 · Aug 25Harrow to Announce Q3 Results, Focus on H2 Revenue Target Achievement Earnings Whispers · Nov 3
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news